The US Food and Drug Administration (FDA) has granted marketing authorisation for LumiThera’s Valeda Light Delivery System to ...

Age-related macular degeneration, or AMD, is a prevalent eye disorder that affects millions globally. This condition can drastically impair vision and make daily tasks much more difficult.

In final guidance NICE said trials have shown Novartis' Beovu has similar efficacy in wet advanced macular degeneration (AMD) to rival Eylea (aflibercept) from Bayer/Regeneron and Novartis ...

Analyst Ross Seymore of Deutsche Bank maintained a Hold rating on Advanced Micro Devices (AMD – Research Report), retaining the price ...

AMD stock is tanking after its Q3 2024 earnings report. Investors aren't impressed by the weakness in non-AI segments as well as a lower-than-expected guidance. We believe the stock is worth ...

Advanced Micro Devices on Tuesday forecast fourth-quarter revenue just shy of estimates and raised its artificial ...

The company reported Q3 results late Tuesday. Advanced Micro Devices, Inc. AMD shares are trading lower by 14% to $142.44 since Wednesday’s open after the company reported third-quarter results.

AMD would discontinue Xilinx production of its complex programmable logic devices (CPLD) in early 2024. Pensando Systems was added to AMD’s portfolio in 2022, with Mipsology to follow in 2023.

In this article, we are going to take a look at where Advanced Micro Devices, Inc. (NASDAQ:AMD) stands against the other AI and semiconductor stocks in BofA’s list that fund managers love and hate.

Advanced Micro Devices is one of the worst S&P 500 stocks Wednesday after the chipmaker's Q4 outlook left Wall Street wanting ...

Advanced Micro Devices, Inc. is gaining ground in AI with ROCm stack, Silo AI acquisition, and MI300X accelerator. Click for ...